Baird analyst David Rescott raised the firm’s price target on Medtronic (MDT) to $91 from $90 and keeps a Neutral rating on the shares. The firm updated its model following Q4 results and said the MedSurg miss clouds an improving return to stability.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- Medtronic’s Strong Growth and Positive Outlook Reinforce Buy Rating Despite Challenges
- Medtronic Q3 Fiscal 2025 Financial Overview
- Medtronic’s Earnings Call Highlights Consistent Growth
- Medtronic’s Strong Profitability and Growth Prospects Earn Buy Rating from Analyst
- Mixed Indicators Lead to Hold Rating for Medtronic: A Balanced Outlook on Future Prospects